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Abstract
Background: Sickle cell disease is characterized by chronic complications that affect almost all body organs. Pancreatic disease 
is  rare in SCD. CA 19-9 is a non-specific surrogate marker for pancreatic disease especially carcinoma. CA 19-9 levels have not 
been evaluated in SCD patients in our environment.
Objectives: The study aimed to compare the levels of  CA 19-9 in homozygous sickle cell disease subjects in steady state with 
those of  (Hb AS) and normal healthy subjects (Hb AA)
Method: Seventy nine subjects including 39 Hb SS, 19 Hb AS and 21 Hb AA subjects were recruited in a cross-sectional study in 
Nnamdi Azikiwe University and Teaching Hospital.  Haemoglobin genotype and CA 19-9 estimation were done using Hb elec-
trophoresis and enzyme linked immunosorbent assay respectively. Data was analyzed with IBM SPSS 21. P value was set at 0.05.
Result: The mean CA 19-9 (U/ml) level in Hb SS, Hb AS and Hb AA were 13.6 ± 7.6, 15.3 ± 9.9, and 20.0 ± 15.9 respectively. 
[Reference value <37U/ml] CA 19-9 was significantly lower in Hb SS compared to Hb AA subjects (p = 0.035). 
Conclusion: Low levels of  CA 19-9 in Hb SS may suggest reduced pancreatic disorders in SCA. 
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Introduction
Sickle cell disease (SCD) is a hereditary disease of  he-
moglobin (Hb) due to the inheritance of  an S gene on 
the β globin chain. The disorder is due to a mutation at 
position six of  the β globin chain resulting in the substitu-
tion of  glutamic acid by valine. Inheritance of  the gene in 
a homozygous form or a compound heterozygous form 
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with another abnormal Hb often results in clinical dis-
ease.1 The disease is characterized by chronic debilitating 
complication often interrupted by episodes of  exacer-
bated symptoms (crises) and periods of  wellness (steady 
state). The disease is associated with increased morbidity 
and mortality and a significant reduction in life expectan-
cy due to associated complications.2
SCD is highly prevalent in sub Saharan Africa with Nige-
ria bearing the highest burden. Nigeria has a prevalence 
rate of  2–3% which brings the affected population esti-
mate between 3.2 and 4.8 million persons, with the na-
tional population estimate of  160 million.3,4
The chronic haemolytic and vaso-occlusive events that 
characterize the disease results in serious tissue-organ 
damage. The entire body tissue-organ-system is affect-
ed by the disease, however pancreatic complications are 
relatively rare. While most body organ complications in 
SCD have been widely studied, there is scarcity of  pub-
lications on pancreatic complications in SCD because of  
its rarity. Balci et al5 reviewed ultrasonographic findings in 
102 SCD subjects in Antakya state hospital, Turkey, only 
4 subjects had echogenic focus on the pancreas but no 
characteristic pancreatic disorder was reported. Ahmed 
et al6 also describe 4 case reports of  acute pancreatitis in 
SCD subjects. They concluded that ischemic injury from 
vaso-occlusive events and biliary stones may underlie the 
pathology in SCD. Kumar et al7 also reported a rare case 
of  acute pancreatitis complicated by pseudocyst forma-
tion. In a review of  52 malignancies in 49 SCD patients, 
William et al did not find any case of  pancreatic carcino-
ma but reported cases of  hepatoma and biliary tract car-
cinoma.8  These highlight the rarity of  pancreatic disease 
in SCD despite the chronic ischaemia that characterize it.
Carbohydrate antigen 19-9 is a glycoprotein that is ex-
pressed on pancreatic and biliary duct cells.9 In health, 
only trace amounts of  the protein is found in plasma but 
in the setting of  pancreatic or biliary tract disease such 
as pancreatitis, carcinoma of  pancreas, biliary tract and 
carcinoma of  the stomach, plasma levels rise exponen-
tially.10 Evaluation of  CA 19-9 levels in sickle cell disease 
patients, may be a valuable predictor of  the onset of  pan-
creatic and hepatobiliary disease including pancreatitis 
and pancreatic carcinoma.
CA19-9 levels is reported to have a sensitivity and speci-
ficity for pancreatic carcinoma in the range of  70 – 90% 
and 68 – 91% respectively11 hence its use as a tumor as-
sociated antigen.12 The hepatobiliary system is one of  the 
common organs to be affected either directly from the 
sickling process or indirectly as a result of  chronic hemo-
lysis, leading to a high incidence of  pigment gall stones, 
and multiple blood transfusions in sickle cell disease.13 
Based on the above and chronic vaso-occlusive events in 
this disease, there is usually ischaemia of  the pancreatic 
tissue, activation of  the pancreatic enzymes and injury to 
the pancreas leading to pancreatitis; hence it is anticipated 
that CA 19-9 levels will be increased in plasma of  these 
subjects. Acute pancreatitis is rarely included as a cause 
of  abdominal pain in patients with sickle cell disease but 
when it occurs, it may result from biliary obstruction, but 
in other instances it might be a consequence of  microves-
sel occlusion causing ischemia.6  There is paucity of  study 
on CA 19-9 levels in SCD. We hypothesize that there is no 
significant difference in CA 19-9 antigen levels in Hb SS 
subjects compared to HB AS and Hb AA subjects. 
We aimed to compare the levels of  CA 19-9 in homozy-
gous sickle cell disease subjects in steady state with those 
that have the trait (carriers)  (Hb AS) and normal healthy 
subjects (Hb AA). To compare CA 19-9 levels in SCD 
subjects based on the disease severity scores and to cor-
relate CA 19-9 levels with age, gender and severity scores 
of  SCD subjects. 
Materials and methods
This was a case control study conducted at the depart-
ment of  hematology, nnamdi azikiwe University Teach-
ing Hospital Nnewi, Anambra state, Nigeria. The case 
group comprised 39 HbSS subjects in steady state, 19 
subjects with Hb AS and Hb 21 Hb AA. Steady state was 
defined as an absence of  febrile episodes, sickle cell crisis 
and blood transfusion for at least 2 weeks, 4 weeks and 
3 months respectively prior to the study14 Sickle cell dis-
ease severity was calculated based on combination of  5 
parameters including haemoglobin level, white cell count, 
number of  hospital admissions, number of  blood trans-
fusions and complications. Scores ≤ 3 were considered 
mild disease, 3 – 7  moderate and > 7  severe, as proposed 
by Okocha et al15 
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Inclusion criteria: The Hb SS subjects must be in  steady 
state; all subjects must be within the age range of  18 – 60 
years. Excluded from the study were non Hb SS sickle cell 
disease subjects (such as HbSβ-thalassemia, HbSC, and 
others) and subjects below 17 and above 60 years of  age. 
Also excluded were patients with known history of  dia-
betes, pancreatitis and pancreatic cancer or hepatobiliary 
complications of  SCD.
 
Blood sample collection and storage
About 5ml of  venous blood was collected aseptically 
from each subject through venipuncture and 2ml dis-
pensed into an EDTA container for the determination 
of  genotype and full blood count. The remaining 3ml 
was dispensed into a plain container and centrifuged at 
5000rpm for 5 minutes. The serum was then extracted 
and stored at -200C and later used for the estimation of  
CA 19-9 level. Normal reference for CA 19-9 are values 
<37U/ml
Haemoglobin electrophoresis on cellulose acetate paper 
was used to determine Hb phenotype using the method 
of  Kohn16 as described by Manafa et al.17 The levels of  
carbohydrate antigen was estimated on solid phase en-
zyme linked immunosorbent assay (ELISA) method as 
described by Steinberg et al.18
 
Ethical consideration
The ethical approval for this research was obtained from 
the Nnamdi Azikiwe University Teaching Hospital ethics 
committee (NAUTHEC). Informed consent of  the sub-
jects was sought and obtained prior to study.
Statistical analysis
Data obtained was analyzed with the IBM-SPSS statistical 
software version 21.  Categorical variables were presented 
as frequency while numerical variables were presented as 
mean and standard deviation. The Student’s t-test and the 
Analysis of  Variance (ANOVA) was used for compari-
son of  mean. Pearson’s correlation coefficient was used 
to correlate CA 19.9 with age, gender and disease severity 
scores. Statistical significance was set at P values < 0.05. 
Result
A total of  79 subjects including 39 Hb SS, 19 Hb AS and 
21 Hb AA subjects participated in the study. The mean 
ages of  the study subjects were 25.9 ± 6.6 years, 24.5 ± 
4.7 years and 24.4 ± 6.8 years respectively. There was no 
significant difference in their mean ages (p = 0.589).
The subjects include 38 males and 41 females. There were 
21, 10 and 10 females in the Hb SS, Hb AS and Hb AA 
sub-groups respectively. Disease severity was determined 
in 25 Hb SS subjects. Eleven Hb SS subjects had moder-
ately severe disease and 2 had severe disease.
Table 1 shows the mean, standard deviation and ranges 
of  the carbohydrate antigen 19.9 in the study subjects. 
Overall, there was no significant difference in the mean 
CA 19.9 levels across study subjects however the post hoc 
analysis showed that the CA 19.9 levels was significantly 
higher in the Hb AA subjects compared to the Hb AS 
subjects (p = 0.035).
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Table 1: Age and CA 19 – 9 levels in study subjects 
 
Variable  Hb Phenotype N Mean ± SD 
(U/ml) 
Range  P value  
  HbSS 39 25.9 ± 6.6 18 – 44    
Age  Hb AS 19 24.5 ± 4.7 18 – 35  0.589 
  Hb AA 21 24.4 ± 6.8 18 – 44    
            
  Hb SS 39 13.6 ± 7.6 2.8 – 36.6    
CA 19.9 Hb AS 18 15.3 ± 9.9 2.0 – 41.0 0.106 
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Table 2 shows a comparison of  CA 19.9 levels between 
males and females in each sub-group. Females across all 
the sub-groups had higher mean CA 19.9 levels compared 
to their male counterparts however the differences in the 
mean were not statistically significant.
Table 2: CA 19 – 9 levels based on sex distribution of study subjects 
 
  Group  Males  Females  T test   
  Hb SS 12.9 ± 7.8 14.15 ± 7.6 -0.505 0.617 
            
CA 19.9 
(U/ml) 
Hb AS 13.6 ± 5.7 17.1 ± 13.0 -0.731 0.475 
      
  Hb AA 17.2 ± 15.7 22.7 ± 16.4 -0.776 0.448 
 
Table  
Table 3 shows the CA 19-9 levels in Hb SS subjects based 
on their disease severity. Subjects with severe disease had 
the highest level 17.2 ± 15.7, but the difference in mean 
was not statistically significant.
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Table 3. CA 19 – 9 levels based on SCD severity scores 
 
  Group N Mean ± SD F value P value 
  Mild  12 12.7 ± 8.6     
            
CA 19.9 
(U/ml) 
Moderate  11 12.5 ± 5.0 0.823 0.452 
            
  Severe  2 17.2 ± 15.7     
 Posthoc analysis showed no significant difference between each of the groups. 
Table 4 shows a correlation between the levels of  CA 19.9 
antigen with age, gender (female) and disease severity in 
the study subjects. There were weak correlations between 
CA 19.9 and age, gender and disease severity in the Hb SS 
subjects. Similarly, there were weak correlations between 
CA 19.9 antigen levels with age and gender in the control 
groups (Hb AS and Hb AA). 
Table 4: Correlation of CA 19 – 9 with age, gender and disease 
severity scores in study subjects 
 
Group    CA 19.9 (U/ml) 
    R P value 
  Age  0.241 0.139 
Hb SS       
  Gender (F) 0.130 0.429 
        
  Disease severity  0.090 0.669 
        
Hb AS Age  0.114 0.653 
        
  Gender (F) 0.054 0.833 
        
Hb AA Age  -0.048 0.841 
        
  Gender (F) 0.208 0.379 
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Discussion
Ca 19-9 is a surrogate marker for pancreatic and biliary 
tract diseases especially carcinoma. Its levels is also ele-
vated in other benign medical conditions of  the pancreas 
and biliary tract including acute and chronic pancreatitis. 
Clinical obvious pancreatic disease are relatively rare in 
SCD however few case reports have been published.5-8 
Furthermore there are rarity of  studies on CA 19-9 levels 
in SCD subjects. In the index study, the mean CA 19 – 9 
levels was significantly elevated in the Hb AA controls 
compared to the Hb SS group and did not differ between 
Hb SS and Hb AS subjects. This suggests that the pres-
ence of  an S haemoglobin may be associated with reduced 
pancreatic injury and damage hence the relatively low CA 
19 – 9 activity. Although we do not know the mechanism 
by which this happens, the fact that pancreatitis and pan-
creatic disease is rare in SCD despite the high incidence 
of  gall stones7 seems to agree with our findings.
We observed that between males and females in each sub-
group, there was no significant difference in the mean CA 
19 – 9 levels though the females had higher values than 
the males. Available data from studies by Selcukbiricik et 
al19, and Gui-Bin20 indicate that there was no significant 
difference between male and females however the males 
in their study had higher mean values.
We also observed that there was no difference in the mean 
CA 19 – 9 levels based on disease severity. Though sub-
jects with severe disease had the highest value, followed 
by those with mild disease, this trend did not show any 
characteristic pattern. However there were relatively few 
subjects with severe disease that participated in the study. 
Correlating CA 19 – 9 levels with age, gender and disease 
severity, there appeared to be a positive correlation with 
age and female gender in Hb SS and Hb AS, but in Hb 
AA, there was a negative correlation with age. However 
these correlations were not statistically significant. In the 
same manner, Malaguarneraa et al21, Leichsenring et al22 
and Pandiaraja et al23 reported positive correlation with 
gender however it was not significant statistically. Our 
findings in relation to correlation with age was similar to 
the observations of  Pandiaraja23 but differed from those 
Duraker et al24 and Sisik et al.25 who reported significant 
correlation with age.
Conclusively, CA 19 – 9 is significantly decreased in SCD 
compared to the normal haemoglobin genotype popula-
tion. There is no difference in CA 19 – 9 levels between 
male and females. Its level did not also change significant-
ly with disease severity. There was no significant correla-
tion with age, gender and disease severity. This work is 
limited by the fact that it was done in one centre. These 
findings should be confirmed preferably by a multi-centre 
study that has a higher sample size.
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